drugset / Trial / NCT05462236
MNK Inhibitor AUM001 in Combination With Either Pembrolizumab or Irinotecan to Treat Metastatic Colorectal Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
The study is a 2-part study of Tinodasertib alone or in combination with Pembrolizumab/Irinotecan in patients with CRC.
Timeline
- Start
- 2023-04-14
- Primary completion
- 2024-09-30
- Completion
- 2026-10-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Irinotecan | Small molecule | 180 mg/m2 | Intravenous |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | Tinodasertib | Small molecule | — | Oral |